PMID- 31886419
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220412
IS  - 2405-6308 (Electronic)
IS  - 2405-6308 (Linking)
VI  - 20
DP  - 2020 Jan
TI  - High versus low dose Stereotactic Body Radiation Therapy for hepatic metastases.
PG  - 45-50
LID - 10.1016/j.ctro.2019.11.004 [doi]
AB  - INTRODUCTION: Stereotactic Body Radiation Therapy (SBRT) is a treatment option 
      for patients with liver metastases. This study evaluated the impact of high 
      versus low dose image-guided SBRT of hepatic metastases. METHODS AND MATERIALS: 
      This is a single-center retrospective study of patients with liver metastases 
      treated with SBRT. For analyses, patients were divided into two groups: </=100 Gy 
      and >100 Gy near-minimum Biological Effective Doses (BED(98%)). The main outcomes 
      were local control (LC), toxicity and overall survival (OS). Cox regression 
      analyses were performed to determine prognostic variables on LC and OS. RESULTS: 
      Ninety patients with 97 liver metastases (77% colorectal) were included. Median 
      follow-up was 28.6 months. The two-year LC rates in the </=100 Gy and >100 Gy 
      BED(98%) group were 60% (CI: 41-80%) and 90% (CI: 80-100%), respectively 
      (p = 0.004). Grade 3 toxicity occurred in 7% vs 2% in the </=100 Gy and >100 Gy 
      group (p = 0.23). Two-year OS rates in the </=100 Gy and >100 Gy group were 48% 
      (CI: 32-65%) and 85% (CI: 73-97%), respectively (p = 0.007). In multivariable Cox 
      regression analyses, group dose and tumor volume were significantly correlated 
      with LC (HR: 3.61; p = 0.017 and HR: 1.01; p = 0.005) and OS (HR: 2.38; p = 0.005 
      and HR: 1.01; p = <0.0001). CONCLUSION: High dose SBRT provides significantly 
      better local control and overall survival than low dose SBRT without increasing 
      toxicity. When surgical resection is not feasible, high dose SBRT provides an 
      effective and safe treatment for liver metastases.
CI  - (c) 2019 The Author(s).
FAU - Kok, Esther N D
AU  - Kok END
AD  - Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, The 
      Netherlands.
FAU - Jansen, Edwin P M
AU  - Jansen EPM
AD  - Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, The 
      Netherlands.
FAU - Heeres, Birthe C
AU  - Heeres BC
AD  - Department of Radiology, Netherlands Cancer Institute, Amsterdam, The 
      Netherlands.
FAU - Kok, Niels F M
AU  - Kok NFM
AD  - Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, The 
      Netherlands.
FAU - Janssen, Tomas
AU  - Janssen T
AD  - Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, The 
      Netherlands.
FAU - van Werkhoven, Erik
AU  - van Werkhoven E
AD  - Medical Biostatistics, Netherlands Cancer Institute, Amsterdam, The Netherlands.
FAU - Sanders, Fay R K
AU  - Sanders FRK
AD  - Department of Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam, The 
      Netherlands.
FAU - Ruers, Theodore J M
AU  - Ruers TJM
AD  - Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, The 
      Netherlands.
AD  - Technical University of Twente, Faculty TNW, Enschede, The Netherlands.
FAU - Nowee, Marlies E
AU  - Nowee ME
AD  - Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, The 
      Netherlands.
FAU - Kuhlmann, Koert F D
AU  - Kuhlmann KFD
AD  - Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, The 
      Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20191127
PL  - Ireland
TA  - Clin Transl Radiat Oncol
JT  - Clinical and translational radiation oncology
JID - 101713416
PMC - PMC6906721
OTO - NOTNLM
OT  - Dose-escalation
OT  - Liver metastases
OT  - Local control
OT  - SBRT
OT  - Stereotactic Body Radiation Therapy
COIS- The authors declare that they have no known competing financial interests or 
      personal relationships that could have appeared to influence the work reported in 
      this paper.
EDAT- 2019/12/31 06:00
MHDA- 2019/12/31 06:01
PMCR- 2019/11/27
CRDT- 2019/12/31 06:00
PHST- 2019/05/22 00:00 [received]
PHST- 2019/11/11 00:00 [revised]
PHST- 2019/11/24 00:00 [accepted]
PHST- 2019/12/31 06:00 [entrez]
PHST- 2019/12/31 06:00 [pubmed]
PHST- 2019/12/31 06:01 [medline]
PHST- 2019/11/27 00:00 [pmc-release]
AID - S2405-6308(19)30111-9 [pii]
AID - 10.1016/j.ctro.2019.11.004 [doi]
PST - epublish
SO  - Clin Transl Radiat Oncol. 2019 Nov 27;20:45-50. doi: 10.1016/j.ctro.2019.11.004. 
      eCollection 2020 Jan.